ArticleFrontiers in oncology2026
Prognostic value of preoperative inflammatory cell-to-HDL cholesterol ratios in patients with non-metastatic clear cell renal cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the prognostic significance of preoperative inflammatory cell-to-high-density lipoprotein cholesterol (HDL-C) ratios in patients with non-metastatic clear cell renal cell carcinoma (ccRCC) undergoing surgery. Methods: A total of 308 patients with non-metastatic ccRCC who underwent radical or partial nephrectomy between 2003 and 2012 were retrospectively enrolled. Preoperative neutrophil-to-HDL-C ratio (NHR), monocyte-to-HDL-C ratio (MHR), platelet-to-HDL-C ratio (PHR), and lymphocyte-to-HDL-C ratio (LHR) were calculated from peripheral blood tests. Time-dependent ROC analyses were performed to compare the prognostic discrimination of these markers for overall survival (OS) and cancer-specific survival (CSS). Kaplan-Meier analysis and Cox proportional hazards regression were used to evaluate survival associations. The incremental prognostic value of NHR and MHR beyond clinicopathological factors was assessed using C-index and decision curve analysis (DCA). Results: Among the four biomarkers, NHR and MHR demonstrated more consistent prognostic discrimination for OS and CSS than PHR and LHR. Patients with high NHR or high MHR had significantly worse OS and CSS (all log-rank P < 0.0001). After adjustment for age, Fuhrman grade, and T stage, both ln-NHR and ln-MHR remained independently associated with poorer OS and CSS (all P < 0.001). Bootstrap resampling demonstrated stable cutoff estimates for NHR and MHR. Incorporation of NHR or MHR into clinicopathological models improved model discrimination and net benefit; however, the incremental prognostic gain was modest. Conclusions: Preoperative NHR and MHR were independent prognostic factors for OS and CSS in patients with non-metastatic ccRCC. Although they provided additional risk stratification beyond conventional clinicopathological factors, their clinical utility requires further validation in multicenter cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.